{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T06:26:56Z","timestamp":1787207216852,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As a rare autoimmune disease, relapsing polychondritis (RP) exhibits individual variations in clinical manifestations, treatment response and prognosis. To date, no biomarkers have been implemented to clinical practice.This study aimed to apply cluster analysis to identify the clinical phenotype, clarify their prognosis predictor, and monitor treatment decisions to improve the outcomes of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 135 RP patients hospitalized in two centers from January 2005 to December 2024 were involved in the study.The K-means clustering algorithm was used as the core clustering tool. The optimal number of clusters(K\u2009=\u20093)was determined through comprehensive evaluation using the Elbow Method and Silhouette Analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cluster analysis identified 3 RP phenotypes.Cluster 1 comprised 45 cases(33.3%),characterized by a hyperinflammatory state and predominant respiratory involvement; Cluster 2 included 11 cases (8.1%),defined by severe and multi-organ involvement Cluster 3 which accounted for 79 cases (58.52%), more than half of the cohort, was predominantly male and exhibited the most favorable prognosis.In contrast, Clusters 1 and 2 were associated with the highest rates of clinical deterioration.Conclusions: This study confirms that relapsing polychondritis is not a single-dimensional disease, but a clinical syndrome with significant heterogeneity. Random forest analysis further identifies that systemic inflammation markers (CRP, CAR, ESR) and sensory organ involvement (hearing impairment and inner ear dysfunction) as the most critical driving factors for distinguishing these subtypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-026-03857-z","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:04:54Z","timestamp":1783778694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating clinical heterogeneity in relapsing polychondritis through unsupervised cluster analysis"],"prefix":"10.1186","volume":"28","author":[{"given":"Wenping","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liguo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lantao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"3857_CR1","doi-asserted-by":"crossref","unstructured":"Lahmer T, Treiber M, von Werder A, Foerger F, Knopf A, Heemann Uwe, et al. Relapsing polychondritis: an autoimmune disease with many faces.Autoimmun Rev. 2010;9(8):540\u20136.","DOI":"10.1016\/j.autrev.2010.02.016"},{"issue":"12","key":"3857_CR2","first-page":"2181","volume":"54","author":"N Hazra","year":"2015","unstructured":"Hazra N, Dregan A, Charlton J, Gulliford MC, D\u2019Cruz DP. Incidence and mortality of relapsing polychondritis in the UK: a population-based cohort study. Rheumatology (Oxford). 2015;54(12):2181\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3857_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/00002281-200401000-00011","volume":"16","author":"PD Kent","year":"2004","unstructured":"Kent PD, Michet CJ Jr. Luthra HS.Relapsing polychondritis. Curr Opin Rheumatol. 2004;16(1):56\u201361.","journal-title":"Curr Opin Rheumatol"},{"key":"3857_CR4","doi-asserted-by":"crossref","unstructured":"Horv\u00e1th A, P\u00e1ll N, Moln\u00e1r K, Kov\u00e1ts T, Surj\u00e1n G, Vicsek T. Pollner P.A nationwide study of the epidemiology of relapsing polychondritis. Clin Epidemiol. 2016;23(8):211\u201330.","DOI":"10.2147\/CLEP.S91439"},{"issue":"1","key":"3857_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11926-015-0549-5","volume":"18","author":"A Vitale","year":"2016","unstructured":"Vitale A, Sota J, Rigante D, Lopalco G, Molinaro F, Messina M, et al. Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives. Curr Rheumatol Rep. 2016;18(1):3.","journal-title":"Curr Rheumatol Rep"},{"key":"3857_CR6","doi-asserted-by":"crossref","unstructured":"Ferrada M, Rimland CA, Quinn K, Sikora K, Kim J, Allen C, et al. Defining clinical subgroups in relapsing polychondritis:a prospective observational cohort study. Arthritis Rheumatol. 2020;72(8):1396\u2013402.","DOI":"10.1002\/art.41270"},{"key":"3857_CR7","doi-asserted-by":"crossref","unstructured":"Lin DF, Yang WQ, Zhang PP, Lv Q, Jin O, Gu JR. Clinical andprognostic characteristics of 158 cases of relapsing polychondritis inChina and review of the literature. Rheumatol Int. 2016;36(7):1003\u20139.","DOI":"10.1007\/s00296-016-3449-8"},{"key":"3857_CR8","doi-asserted-by":"crossref","unstructured":"McAdam LP, O\u2019Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Med (Baltim). 1976;55(3):193\u2013215.","DOI":"10.1097\/00005792-197605000-00001"},{"issue":"11","key":"3857_CR9","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1007\/s10067-021-05827-z","volume":"40","author":"XY Cao","year":"2021","unstructured":"Cao XY, Zhao MZ, Li HJ, Xu D, Li MT, Zhang X, et al. Three new inflammatory markers C reactive protein to albumin ratio, neutrophil to lymphocyte ratio, and platelet to lymphocyte ratio correlated with relapsing polychondritis disease activity index. Clin Rheumatol. 2021;40(11):4685\u201391.","journal-title":"Clin Rheumatol"},{"key":"3857_CR10","doi-asserted-by":"publisher","first-page":"1274677","DOI":"10.3389\/fimmu.2023.1274677","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu YM, Cheng LL, Zhao MZ, Zhan HT, Li XM, Huang Y, et al. Development and validation of diagnostic and activity-assessing models for relapsing polychondritis based on laboratory parameters. Front Immunol. 2023;14:1274677.","journal-title":"Front Immunol"},{"key":"3857_CR11","doi-asserted-by":"crossref","unstructured":"Arnaud L, Devilliers H, Peng SL, Mathian A, Costedoat-Chalumeau N, Buckner J, et al. The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. Autoimmun Rev. 2012;12(2):204\u20139.","DOI":"10.1016\/j.autrev.2012.06.005"},{"key":"3857_CR12","doi-asserted-by":"crossref","unstructured":"Salvatori B, Wegener S, Kotzaeridi G, Herding A, Eppel F, Dressler-Steinbach I, et al. Identification and validation of gestational diabetes subgroups by data. -driven cluster analysis. Diabetologia. 2024;67(8):1552\u201366.","DOI":"10.1007\/s00125-024-06184-7"},{"key":"3857_CR13","doi-asserted-by":"crossref","unstructured":"Park SY, Jung HW, Lee JM, Shin B, Kim HJ, Kim MH, et al. Novel Trajectories for Identifying Asthma Phenotypes: A Longitudinal Study in Korean Asthma Cohort, COREA. J Allergy Clin Immunol Pract. 2019;7(6):1850\u20137.","DOI":"10.1016\/j.jaip.2019.02.011"},{"key":"3857_CR14","doi-asserted-by":"crossref","unstructured":"Adegunsoye A, Oldham JM, Chung JH, Montner SM, Lee C, Witt LJ, et al. Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. Chest. 2018;153(2):349\u201360.","DOI":"10.1016\/j.chest.2017.09.026"},{"issue":"12","key":"3857_CR15","first-page":"2992","volume":"68","author":"D J\u00e9r\u00e9mie","year":"2016","unstructured":"J\u00e9r\u00e9mie D, Nathalie Costedoat-Chalumeau, Damien S\u00e8ne, Judith Cohen-Bittan,Ga\u00eblle Leroux, Charlotte Dion, et al. Relapsing polychondritis can be characterized by 3 different clinical phenotypes:Analysis of a recent series of 142 patients.Arthritis &. Rheumatol. 2016;68(12):2992\u20133001","journal-title":"Rheumatol"},{"issue":"1","key":"3857_CR16","first-page":"225","volume":"16","author":"L Zhang","year":"2021","unstructured":"Zhang L, Yun S, Wu TG, He YJ, Guo JY, Han LS, et al. Clinical patterns and the evolution of relapsing polychondritis based on organ involvement: a Chinese retrospective cohort study.Orphanet. J Rare Dis. 2021;16(1):225.","journal-title":"J Rare Dis"},{"key":"3857_CR17","first-page":"96","volume":"24","author":"M Zeuner","year":"1997","unstructured":"Zeuner M, Straub RH, Rauh G, Albert ED, Scholmerich J, Lang B. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol. 1997;24:96\u2013101.","journal-title":"J Rheumatol"},{"key":"3857_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2492\/inflammregen.34.149","volume":"34","author":"H Oka","year":"2014","unstructured":"Oka H, Yamano Y, Shimizu J, Yudoh K, Suzuki N. A large-scale survey of patients with relapsing polychondritis in japan. Inflamm regen. 2014;34:149\u201356.","journal-title":"Inflamm regen"},{"key":"3857_CR19","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease.N. Engl J Med. 2020;383(27):2628\u201338.","journal-title":"Engl J Med"},{"issue":"6","key":"3857_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41584-024-01113-9","volume":"20","author":"P Mertz","year":"2024","unstructured":"Mertz P, Costedoat-Chalumeau N, Ferrada MA, Moulis G, Mekinian A, Grayson PC, et al. Relapsing polychondritis: clinical updates and new differential diagnoses. Nat Rev Rheumatol. 2024;20(6):347\u201360.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"3857_CR21","doi-asserted-by":"publisher","first-page":"1396e402","DOI":"10.1002\/art.41270","volume":"72","author":"M Ferrada","year":"2020","unstructured":"Ferrada M, Rimland CA, Quinn K, Sikora K, Kim J, Allen C, et al. Defining clinical subgroups in relapsing polychondritis: a prospective observational cohort study. Arthritis Rheumatol. 2020;72(8):1396\u2013402.","journal-title":"Arthritis Rheumatol"},{"issue":"42","key":"3857_CR22","doi-asserted-by":"publisher","first-page":"e12837","DOI":"10.1097\/MD.0000000000012837","volume":"97","author":"J Shimizu","year":"2018","unstructured":"Shimizu J, Yamano Y, Kawahata K, Suzuki N. Relapsing polychondritis patients were divided into three subgroups: patients with respiratory involvement (R subgroup), patients with auricular involvement (A subgroup), and overlapping patients with both involvements (O subgroup), and each group had distinctive clinical characteristics. Med (Baltim). 2018;97(42):e12837.","journal-title":"Med (Baltim) Oct"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03857-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03857-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03857-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T06:20:34Z","timestamp":1787206834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03857-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3857"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03857-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving humans were approved by Studies on material of human origin were approved by the ethics committee of the Ethics Committee of First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital and the ethics committee of the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University. Informed consent was obtained from all patients\/participants. The studies were conducted in accordance with the local legislation and institutional requirements.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have agreed to the publication of this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"153"}}